Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sanofi's PARP Inhibitor Plus Chemo May Be A Lethal One-Two Punch In Triple-Negative Breast Cancer

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

News that Sanofi-Aventis' PARP inhibitor iniparib conferred "significant clinical benefit" in a proof of concept study against metastatic triple-negative breast cancer – published online Jan. 5 by the New England Journal of Medicine – has generated excitement about the approach, but a Phase III study powered for statistically meaningful results in overall and progression-free survival will tell the tale.

You may also be interested in...

Sanofi Oncology’s Transformation Rests On Fedratinib, At Least In The Near-Term

The JAK2 inhibitor for myelofibrosis is the company’s most advanced oncology candidate and will be an anchor for Sanofi as it looks to build a portfolio of next-generation cancer drugs after the late-stage failure of the PARP inhibitor iniparib.

Making Gains Against Triple-Negative Breast Cancer

Researchers reported on new approaches to the knotty problem of triple-negative breast cancer, using genomics to identify ways of targeting the intractable disease with drugs already in the industry pipeline, at the San Antonio Breast Cancer Symposium Dec. 4-8.

Ovarian Cancer: Roche's Avastin And Others Show Potential, But Also Raise The "Value" Question

Roche/Genentech rolled out yet more data on Avastin (bevacizumab) in ovarian cancer at the American Society of Clinical Oncology meeting in Chicago June 3-7, but other companies also had promising results for new therapies that might help break the historical 24-month survival barrier for the difficult cancer.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts